Back HCV Treatment Approved HCV Drugs

Approved HCV Drugs

Studies Show High Cure Rates for Interferon-free Hepatitis C Treatment

An all-oral combination of daclatasvir (Daklinza) plus asunaprevir led to sustained virological response (SVR) in 82%-90% of treatment-naive and previously treated people with hepatitis C virus genotype 1b, while a regimen of sofosbuvir (Sovaldi) plus simeprevir (Olysio) cured 92%-94% of hepatitis C patients with or without cirrhosis, according to findings from a pair of clinical trials reported in the July 28 advance online edition of The Lancet.

alt

Read more:

IDWeek 2013: Older People Respond Equally Well to Telaprevir Triple Therapy for Hepatitis C

Interferon-based therapy with telaprevir (Incivek or Incivo) produced a similar cure rate with no notable increase in side effects or treatment discontinuation for genotype 1 chronic hepatitis C patients over age 60, Japanese researchers reported at the second IDWeek conference held recently in San Francisco.

alt

Read more:

EASL 2013: 12 Weeks of Telaprevir Triple Therapy Adequate for Some Hep C Patients

Nearly 90% of genotype 1 chronic hepatitis C patients with favorable response factors including the IL28B CC gene variant achieved a cure with just 12 weeks of telaprevir (Incicek or Incivo) plus pegylated interferon/ribavirin, rising to 97% for those treated for 24 weeks, researchers reported at the recent EASL International Liver Congress (EASL 2013) in Amsterdam.

alt

Read more:

Telaprevir Triple Therapy Shows Activity Against HCV Genotype 4

The HCV protease inhibitor telaprevir (Incivek or Incivo) in combination with pegylated interferon and ribavirin reduced viral levels by more than 4 log in people with genotype 4 hepatitis C in a short Phase 2a study, researchers reported in the September 15, 2013 Journal of Infectious Diseases.

alt

Read more:

DDW 2013: Prior Non-responders Can Achieve Good SVR Rates with Boceprevir Triple Therapy

People previously treated with interferon-based therapy can achieve good results when retreated with boceprevir (Victrelis) triple therapy, according to final results from the PROVIDE study presented at the Digestive Disease Week meeting (DDW 2013) last month in Orlando. Prior relapsers had the best response, but even 41% of prior null responders achieved a cure.

alt

Read more: